Enorama Pharma AB Market Cap ($6.69 Million)
Market Cap & Net Worth: Enorama Pharma AB (ERMA)
Enorama Pharma AB market cap. Enorama Pharma AB (ST:ERMA) has a market capitalization of $6.69 Million (Skr62.21 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27894 globally and #609 in its home market, demonstrating a 7.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enorama Pharma AB's stock price Skr0.83 by its total outstanding shares 74588682 (74.59 Million). Also see ERMA cash generation efficiency for how efficiently the company converts equity into cash flow.
Enorama Pharma AB Market Cap History (2016–2026)
Enorama Pharma AB market cap history from 2016 to 2026. Data shows change from $70.67 Million to $6.69 Million (-19.27% CAGR). Check Enorama Pharma AB (ERMA) share price today for real-time trading data and today's change.
Index Memberships
Enorama Pharma AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.35 Billion | 0.04% | #175 of 281 |
Weight: Enorama Pharma AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enorama Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enorama Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ERMA year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.60x
Enorama Pharma AB's market cap is 5.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $70.67 Million | $3.99 Million | -$7.84 Million | 17.71x | N/A |
| 2017 | $628.16 Million | $1.57 Million | -$8.76 Million | 399.37x | N/A |
| 2018 | $471.98 Million | $5.26 Million | -$16.34 Million | 89.80x | N/A |
| 2019 | $325.09 Million | $7.61 Million | -$24.72 Million | 42.71x | N/A |
| 2020 | $265.69 Million | $2.15 Million | -$23.90 Million | 123.81x | N/A |
| 2021 | $178.60 Million | $11.04 Million | -$28.54 Million | 16.18x | N/A |
| 2022 | $29.30 Million | $6.85 Million | -$41.78 Million | 4.28x | N/A |
| 2023 | $24.88 Million | $1.36 Million | -$44.61 Million | 18.32x | N/A |
| 2024 | $26.97 Million | $15.77 Million | -$43.81 Million | 1.71x | N/A |
| 2025 | $15.33 Million | $2.74 Million | -$75.14 Million | 5.60x | N/A |
Competitor Companies of ERMA by Market Capitalization
Companies near Enorama Pharma AB in the global market cap rankings as of November 4, 2026. Also see ERMA total asset value for a full breakdown of the balance sheet.
Key companies related to Enorama Pharma AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Enorama Pharma AB (2016–2026)
Market capitalization of Enorama Pharma AB from 2016 to today. Between 2016 and today, Enorama Pharma AB's market cap moved from $70.67 Million to $ 6.69 Million, with a yearly change of -19.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr6.69 Million | -56.34% |
| 2025 | Skr15.33 Million | -43.15% |
| 2024 | Skr26.97 Million | +8.39% |
| 2023 | Skr24.88 Million | -15.07% |
| 2022 | Skr29.30 Million | -83.60% |
| 2021 | Skr178.60 Million | -32.78% |
| 2020 | Skr265.69 Million | -18.27% |
| 2019 | Skr325.09 Million | -31.12% |
| 2018 | Skr471.98 Million | -24.86% |
| 2017 | Skr628.16 Million | +788.89% |
| 2016 | Skr70.67 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Enorama Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.69 Million USD |
| MoneyControl | $6.69 Million USD |
| MarketWatch | $6.69 Million USD |
| marketcap.company | $6.69 Million USD |
| Reuters | $6.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells tobacco-free white snus in Sweden. It offers its products under the NIC-S brand name. The company was incorporated in 2006 and is based in Stockholm, Sweden.